Krystal Biotech (KRYS)
(Delayed Data from NSDQ)
$137.35 USD
+2.41 (1.79%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $135.23 -2.12 (-1.54%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
KRYS 137.35 +2.41(1.79%)
Will KRYS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KRYS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KRYS
KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook
Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates
KRYS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Krystal Biotech, Inc. (KRYS) to Report Q2 Results: Wall Street Expects Earnings Growth
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up
Other News for KRYS
What 8 Analyst Ratings Have To Say About Krystal Biotech
Chardan Capital Maintains Buy Rating for Krystal Biotech (KRYS) | KRYS Stock News
Citigroup Maintains Neutral Rating on KRYS, Lowers Price Target | KRYS Stock News
Krystal Biotech Inc (KRYS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results